past
year
seen
emerg
two
novel
coronavirus
infect
human
result
high
morbid
mortal
thought
coronaviru
infect
associ
mild
respiratori
diseas
littl
reason
develop
novel
therapeut
option
coronaviru
infect
global
outbreak
sar
fatal
rate
recent
emerg
merscov
infect
well
recent
recogn
coronaviru
infect
demonstr
need
investig
treatment
option
sever
coronaviru
infect
merscov
first
identifi
june
year
old
patient
middl
east
develop
clinic
symptom
sign
similar
sar
eventu
die
multi
organ
failur
zaki
et
al
novel
coronaviru
isol
initi
call
hcovemc
renam
middl
east
respiratori
syndrom
coronaviru
merscov
de
groot
et
al
sinc
viru
continu
caus
sever
zoonot
human
diseas
middl
east
sometim
associ
outbreak
humantohuman
transmiss
within
health
care
facil
arabi
et
al
chan
et
al
perlman
mccray
may
larg
outbreak
occur
korea
korean
societi
infecti
korean
societi
healthcareassoci
infect
prevent
highlight
threat
global
public
health
secur
previous
show
merscov
replic
human
upper
lower
respiratori
tract
infect
noncili
bronchial
epitheli
cell
bronchiolar
epitheli
cell
type
type
ii
alveolar
pneumocyt
endotheli
cell
use
ex
vivo
explant
cultur
furthermor
show
contrast
sarscov
infect
merscov
infect
elicit
lower
proinflammatori
cytokin
respons
includ
type
iii
interferon
evas
innat
immun
induct
reduc
interferon
ifn
respons
suggest
exogen
ifn
may
possibl
treatment
option
human
merscov
infect
previou
studi
show
pegyl
ifn
exhibit
potent
antivir
effect
merscov
sarscov
cell
cultur
macaqu
model
de
wild
et
al
falzarano
et
al
propos
due
lack
merscov
homolog
sarscov
protein
block
ifn
induc
transloc
factor
essenti
signal
via
ifn
receptor
lead
induct
ifn
associ
antivir
gene
macaqu
model
ifn
use
togeth
ribavirin
led
improv
clinic
symptom
follow
merscov
infect
microarray
analysi
show
lower
express
inflammatori
gene
falzarano
et
al
nevertheless
number
recent
clinic
studi
report
ifn
ribavirin
combin
improv
longterm
surviv
benefici
patient
receiv
treatment
late
infect
altawfiq
et
al
omrani
et
al
indic
need
consid
therapeut
combin
treat
merscov
infect
cyclosporin
cyclosporin
csa
deriv
shown
inhibit
merscov
replic
vitro
de
wild
et
al
demonstr
csa
could
restor
type
ifn
express
upon
hepat
c
rotaviru
viru
infect
liu
et
al
shen
et
al
combin
use
csa
type
ifn
shown
inhibit
hepat
c
viru
replic
trigger
greater
virolog
respons
ifn
treatment
alon
henri
et
al
inou
et
al
csa
known
immun
suppress
function
nonimmunosuppress
cyclophilin
inhibitor
tri
combin
ribavirin
merscov
infect
though
vitro
effect
merscov
sarscov
translat
benefit
mous
model
de
wild
et
al
report
individu
combin
effect
csa
inhibit
merscov
replic
vitro
human
lung
bronchu
ex
vivo
explant
cultur
model
found
combin
use
csa
inhibitori
effect
merscov
infect
replic
well
induct
interferon
stimul
gene
isg
shed
light
potenti
use
combin
cure
merscov
infect
ex
vivo
explant
cultur
human
respiratori
tract
obtain
patient
undergo
surgeri
queen
mari
hospit
accord
previous
establish
criteria
hui
et
al
select
area
morpholog
normal
lung
histolog
perform
control
sampl
sampl
subject
viru
cultur
bacteri
cultur
intrins
diseas
infect
resect
lung
specimen
use
research
project
approv
local
institut
review
board
uw
fresh
biopsi
human
bronchi
lung
sampl
human
lung
remov
surgeri
part
clinic
care
surplu
routin
diagnost
requir
ex
vivo
infect
human
bronchu
lung
perform
previous
publish
chan
et
al
brief
bronchial
mucosa
place
surgic
spong
apic
epitheli
surfac
face
upward
lung
parenchym
tissu
place
wellplat
directli
ml
cultur
medium
human
betacoronaviru
lineag
c
viru
hcovemc
provid
r
fouchier
erasmu
mc
fig
evalu
chang
merscov
replic
addit
csa
combin
two
agent
vero
cell
csa
andor
uml
use
data
shown
mean
standard
error
mean
three
repres
experi
analyz
twoway
anova
follow
bonferroni
post
hoc
test
p
p
p
fig
evalu
chang
merscov
replic
addit
csa
combin
two
agent
human
bronchu
b
human
lung
explant
cultur
csa
andor
uml
use
data
shown
mean
standard
error
mean
least
three
independ
experi
analyz
twoway
anova
follow
bonferroni
post
hoc
test
p
p
p
rotterdam
netherland
use
prototyp
merscov
examin
efficaci
differ
treatment
fresh
bronchial
lung
tissu
infect
hcovemc
viral
titer
tcid
ml
h
wash
ml
pb
room
temperatur
three
time
remov
unbound
viru
fresh
cultur
medium
regimen
cyclosporin
novarti
pharmaceut
corpor
andor
uml
ifn
kadmon
pharmaceut
ad
cultur
treatment
replenish
interv
supernat
infect
cultur
collect
hpi
titrat
infecti
viru
use
tcid
assay
hcovemc
increas
viru
titer
time
provid
evid
product
viru
replic
tissu
collect
hpi
rna
extract
fixat
formalin
immunohistochem
stain
merscov
nucleocapsid
protein
np
use
antibodi
provid
dr
r
baric
cleav
caspas
cell
signal
technolog
vero
cell
incub
alphainterferon
andor
cyclosporin
determin
optim
inhibit
applic
ex
vivo
sampl
supplementari
fig
vero
atcc
cell
line
cultur
minimum
essenti
medium
mem
gibco
supplement
fetal
bovin
serum
fb
gibco
unitsml
penicillin
streptomycin
human
lung
microvascular
endotheli
cell
prepar
fresh
human
lung
select
cell
use
antihuman
antibodi
abcam
dynabead
cell
separ
system
thermofish
isol
cell
maintain
medium
supplement
fb
lonza
cell
use
studi
maintain
co
humidifi
atmospher
viral
replic
kinet
tissu
cultur
infecti
dose
tcid
ml
titrat
confluent
tissu
cultur
plate
vero
cell
prepar
day
viru
titrat
assay
cell
wash
pb
replenish
dmem
fb
unitsml
penicillin
streptomycin
serial
dilut
effect
andor
csa
protein
express
level
merscov
nucleocapsid
phosphorylationactiv
protein
b
phosphorylationactiv
level
protein
involv
mapk
pathway
c
shown
band
three
independ
experi
quantifi
densitometri
use
imagej
softwar
normal
expressionactiv
level
indic
histogram
csa
andor
uml
use
log
log
virusinfect
cultur
supernat
ad
onto
well
quadrupl
plate
observ
cpe
daili
seven
day
endpoint
viral
dilut
lead
cpe
inocul
well
estim
use
karber
method
design
one
tcid
ml
bronchial
lung
fragment
homogen
use
tissueruptor
qiagen
hilden
germani
rlt
lysi
buffer
betamercaptoethanol
ice
rna
extract
carri
use
rneasi
mini
kit
qiagen
hilden
germani
follow
manufactur
instruct
addit
dnasetreat
elut
rnase
free
water
ng
total
rna
use
firststrand
cdna
synthesi
primescript
rt
reagent
kit
system
takara
express
key
gene
involv
cell
signal
mediat
interferon
receptor
ligand
profil
rtpcrbase
rt
profil
interferon
receptor
array
qiagen
rtpcr
reaction
perform
plate
format
use
realtim
pcr
system
thermo
fisher
scientif
fold
chang
ifn
gene
express
experiment
sampl
rel
control
sampl
eg
mockinfect
calcul
use
method
valu
sampl
normal
total
housekeep
gene
hypoxanthin
phosphoribosyltransferas
ribosom
protein
dehydrogenas
gapdh
actb
data
analyz
rt
profil
pcr
array
data
analysi
templat
gene
express
chang
greater
fold
consid
signific
signific
gene
chang
confirm
individu
qpcr
cell
lysat
prepar
use
ripa
buffer
heat
min
protein
resolv
sdspage
transfer
pvdf
membran
mous
antiactin
millipor
rabbit
antimerscov
nucleocapsid
protein
kindli
provid
dr
r
baric
use
load
infect
control
protein
interest
includ
phosphorakt
akt
phosphormtor
mtor
also
detect
cell
signal
technolog
membran
incub
respect
hrp
conjug
secondari
antibodi
signal
differ
protein
interest
detect
enhanc
chemiluminesc
method
experi
perform
independ
three
differ
donor
result
shown
figur
includ
calcul
mean
standard
error
mean
comparison
among
three
group
analyz
use
twoway
analysi
varianc
anova
bonferroni
multiplecomparison
posthoc
test
group
statist
signific
defin
p
viral
replic
vero
cell
cultur
determin
regimen
cyclosporin
uml
ifn
separ
combin
although
signific
reduct
viral
titr
ifnalfacon
csa
use
separ
cultur
treat
agent
combin
significantli
lower
viral
titr
h
compar
cultur
treat
singl
drug
well
untreat
cell
fig
hcovemc
replic
untreat
ex
vivo
lung
bronchial
tissu
titr
bronchu
higher
lung
especi
hpi
similar
replic
cell
line
viral
replic
reduc
treatment
h
postinfect
fig
b
ex
vivo
cultur
bronchu
fig
combin
csa
ifn
treatment
significantli
lower
viral
titr
compar
csa
ifn
treatment
alon
ex
vivo
lung
cultur
combin
therapi
csa
therapi
result
significantli
lower
viral
titr
untreat
cultur
ifn
treatment
alon
fig
howev
effect
csa
alon
compar
combin
therapi
data
suggest
addit
synergist
effect
ifn
csa
limit
hcovemc
replic
bronchu
lung
bronchu
explant
tissu
collect
fix
formalin
infect
merscov
nucleocapsid
protein
np
use
indic
hcovemc
infect
fig
extens
hcovemc
infect
found
bronchial
ciliat
noncili
cell
alveolar
pneumocyt
without
treatment
bronchial
explant
found
treatment
could
inhibit
hcovemc
infect
level
inhibitori
effect
infect
greatest
combin
treatment
group
csa
alon
inhibit
least
hcovemc
infect
furthermor
ex
vivo
lung
explant
infect
hcovemc
infect
significantli
inhibit
treatment
group
compar
control
treatment
next
determin
abil
differ
treatment
reduc
cellular
apoptosi
induc
hcovemc
infect
stain
cleav
caspas
fig
extens
stain
cleav
caspas
found
ex
vivo
bronchial
lung
explant
without
treatment
level
stain
reduc
treatment
group
bronchu
tissu
csa
combin
treatment
group
greatest
impact
reduc
cleav
caspas
stain
effect
csa
alon
lowest
bronchu
tissu
lung
tissu
level
apoptosi
minim
csa
combin
treat
csa
treat
group
show
abil
csa
combin
treatment
inhibit
hcovemc
replic
investig
potenti
antivir
mechan
underli
inhibit
use
interferon
receptor
pcr
array
data
show
combin
treatment
csa
potent
effect
induc
interferonstimul
gene
isg
lung
hpi
bronchial
hpi
tissu
fig
combin
treatment
group
also
induc
express
ifn
ifn
gamma
receptor
lung
bronchu
fig
isg
highli
induc
data
verifi
independ
qpcr
use
lung
bronchu
tissu
supplementari
fig
vero
cell
line
data
shown
induct
isg
signific
compar
treatment
group
evalu
possibl
mechan
relat
augment
isg
level
associ
ifn
csa
examin
phosphoryl
level
akt
mtor
mapk
molecul
link
transcript
activ
interferonsensit
respons
element
isr
perform
experi
primari
human
cell
addit
continu
celllin
therefor
use
human
lung
microvascular
endotheli
cell
hmvecl
associ
extrapulmonari
dissemin
hcovemc
hcovemc
replic
well
primari
human
alveolar
epitheli
cell
vitro
demonstr
hcovemc
could
infect
lung
endotheli
cell
previou
studi
data
show
hmvecl
highli
suscept
hcovemc
infect
csa
combin
treatment
group
greatest
impact
reduc
hcovemc
replic
fig
treatment
dosag
cytotox
cell
use
supplementari
fig
line
viru
replic
data
confirm
csa
treat
group
potent
reduc
hcovemc
np
express
either
ifn
csa
alon
express
phosphoryl
compar
increas
ifn
treat
combin
csa
treat
group
fig
suggest
effect
combin
treatment
independ
jakstat
pathway
next
examin
mapk
aktmtor
pathway
fig
phosphoryl
level
combin
treatment
group
lowest
similar
csa
treat
group
contrari
phosphoryl
level
akt
lowest
combin
treatment
group
phosphoryl
level
mtor
compar
among
group
fig
indic
benefici
effect
combin
therapi
may
link
akt
mtor
translat
control
isg
mer
continu
caus
diseas
arabian
peninsula
high
case
fatal
hospit
patient
still
proven
specif
antivir
therapi
diseas
despit
appar
benefit
interferon
therapi
rhesu
macaqu
marmoset
interferon
therapi
translat
clinic
benefit
clinic
case
mer
review
altawfiq
memish
arabi
et
al
may
part
relat
late
present
patient
compar
laboratori
set
lack
good
experiment
anim
model
hamper
progress
antivir
therapi
mer
ex
vivo
cultur
human
bronchu
lung
provid
altern
complementari
option
investig
therapeut
agent
still
limit
sever
cov
infect
studi
patient
may
present
health
care
set
day
exposur
current
beyond
abil
maintain
ex
vivo
tissu
studi
find
combin
interferon
short
term
cyclosporin
fig
may
worthi
pursuit
clinic
trial
set
previous
drug
use
singli
combin
de
wild
et
al
ex
vivo
cultur
show
signific
decreas
viru
replic
combin
treatment
use
compar
singl
treatment
also
reflect
greater
number
isg
upregul
compar
mock
singl
treatment
increas
isg
may
thu
dampen
potenti
immun
suppress
effect
csa
use
singl
agent
combin
treatment
type
interferon
cyclosporin
also
mitig
extent
apoptosi
caus
hcovemc
studi
fig
differ
therapeut
modal
consid
evalu
clinic
trial
suggest
ifn
csa
combin
therapi
consid
recent
review
also
note
need
evalu
combin
therapi
altawfiq
memish
csa
small
molecul
immunosuppress
immunostimul
protein
favor
cell
convers
antivir
state
sinc
mechan
underli
increment
isg
combin
unclear
tri
identifi
possibl
mechan
behind
higher
induct
level
isg
combin
treatment
type
ifn
csa
treatment
group
canon
type
ifn
signal
activ
jakstat
pathway
essenti
member
form
complex
bind
isr
control
isg
express
ivashkiv
donlin
sinc
activ
level
combin
treatment
similar
even
slightli
lower
treatment
alon
fig
believ
extra
isg
induct
could
result
signal
cascad
independ
jakstat
signal
therefor
tri
determin
whether
combin
treatment
would
effect
aktmtor
pathway
turn
translat
control
isg
kaur
et
al
kroczynska
et
al
saleiro
et
al
result
show
mtor
activ
affect
combin
treatment
decreas
phosphoryl
level
akt
combin
treatment
group
may
relat
signal
cascad
link
akt
therebi
like
aktmtor
involv
enhanc
isg
level
doubl
treatment
furthermor
also
examin
mapk
activ
level
also
link
isr
separ
platania
saleiro
et
al
result
hcovemc
induc
phosphoryl
lim
et
al
reduc
due
effect
csa
may
contribut
inhibit
mercov
replic
level
result
match
elev
isg
level
therefor
like
csa
type
ifn
combin
therapi
use
altern
pathway
enhanc
antivir
effect
enhanc
isg
induct
act
directli
indirectli
isr
supplementari
fig
conclus
demonstr
csa
potent
therapeut
combin
inhibit
hcovemc
replic
vitro
ex
vivo
result
higher
isg
express
combin
may
worth
consid
futur
clinic
trial
none
